title: [Von Willebrand disease: characteristics and response to desmopressin. Study of 103 cases].
abstract: BACKGROUND
  To describe the main characteristics and response to desmopressin infusion in 103 patients suffering from von Willebrand disease (vWD).
  
  
  METHODS
  The criteria for diagnosis were (except for type 2N) the coexistence of von Willebrand factor ristocetin cofactor (vWF:RCo) activity < 50 U/dl with bleeding disease or one of the following data: von Willebrand factor antigen (vWF:Ag) activity < 50 U/dl, factor VIII (FVIII) activity < 50 U/dl or the existence of a increased bleeding time (BT). Multimeric studies of vWF were performed in 51 cases and ristocetin induced platelet aggregation (RIPA) was also performed.
  
  
  RESULTS
  Spontaneous bleeding was found in 36 patients, while in 18 cases the diagnosis was done after surgical bleeding. Thirteen patients (6 presenting with mild bleeding) were studied for abnormalities in the routine preanestesic tests. Other 22 patients were diagnosed with vWD by familial studies. There were 3 patients with type 2B, 1 case with type 2N and other patient with type 3. BT was found increased in 26 out of 58 patients. The activities of vWF:CoR and vWF:Ag were 38.4 (9.4) U/dl and 45.8 (23.2) U/dl, respectively, while the activity of FVIII was 49.9 (20.8) U/dl. Prophylactic DDAVP (desmopressin) was infused in 32 patients. After 1 h, basal activities of vWF:CoR and vWF:Ag were increased by 3.1 (3.2) and 3.4 (3.1) times, respectively, and maintained for 3 h. FVIII activity increased 3.6 (2.3) times the basal levels decreasing after 3 h (2.9 [2.1]; p < 0.01). The BT was corrected in 8 out of ten patients.
  
  
  CONCLUSIONS
  vWD is a major cause of surgical bleeding. Preanestesic anamnesis and coagulation tests can be useful to identify vWD. Many patients with vWD have normal BT. A failure in the response to desmopressin infusion is unusual.
authors.affiliation: Servicio de Hematología, Hospital Ramón, Cajal, Madrid.
authors.forename: J M
authors.initials: JM
authors.lastname: César
authors.forename: A G
authors.initials: AG
authors.lastname: Avello
authors.forename: A
authors.initials: A
authors.lastname: Vecino
authors.forename: C
authors.initials: C
authors.lastname: Cerveró
authors.forename: J G
authors.initials: JG
authors.lastname: Laraña
authors.forename: I F
authors.initials: IF
authors.lastname: Fuertes
authors.forename: J
authors.initials: J
authors.lastname: Villarrubia
authors.forename: J
authors.initials: J
authors.lastname: López
authors.forename: J P
authors.initials: JP
authors.lastname: de Oteyza
authors.forename: J L
authors.initials: JL
authors.lastname: Velasco
authors.forename: A
authors.initials: A
authors.lastname: Cantalapiedra
authors.forename: P
authors.initials: P
authors.lastname: Herrera
authors.forename: S
authors.initials: S
authors.lastname: Herrero
authors.forename: J L
authors.initials: JL
authors.lastname: Navarro
mesh_terms: D003894:Deamino Arginine Vasopressin / Q000627:therapeutic use*; D005260:Female; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D014842:von Willebrand Diseases / Q000188:drug therapy*
chemical_list: D006490:Hemostatics; D003894:Deamino Arginine Vasopressin